Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies.
Autoimmune liver diseases
Disease prevention
ELF score
Pre-autoimmunity
Primary biliary cholangitis
Journal
Auto- immunity highlights
ISSN: 2038-0305
Titre abrégé: Auto Immun Highlights
Pays: England
ID NLM: 101532391
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
08
07
2019
accepted:
24
09
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Anti-mitochondria autoantibodies (AMA) occur in > 95% primary biliary cholangitis (PBC) patients. Biochemically normal AMA-positive (BN/AMA+) individuals, occasionally noticed by indirect immunofluorescence (IIF) on HEp-2 cells and confirmed in AMA-specific assays, may represent early stages of PBC. The Enhanced Liver Fibrosis (ELF) score is a surrogate marker for liver fibrosis. This prospective study investigated the ELF score in BN/AMA+ individuals and PBC patients, considering autoantibody avidity and serum levels along the years. 327 samples from 35 PBC and 59 BN/AMA+ were prospectively obtained in average 3.83 (range 0.50-7.40) years apart. Samples were tested by IIF on rat-kidney (IIF-AMA), western-blot for AMA (WB-AMA), and ELISA for antibodies against pyruvate-dehydrogenase (PDC-E2), gp210, sp100 and CENP-A/B. Anti-PDC-E2 avidity was determined by 6 M urea-elution ELISA. Alkaline phosphatase (ALP), gamma glutamyl transferase (ɣGT) and ELF score were measured by automated methods. Along the follow-up period BN/AMA+ subjects and PBC patients presented significant increase in serum anti-PDC-E2 (mean 10.45% and 8.86% per year; respectively), anti-PDC-E2 avidity (3.02% and 4.94%/year) and ELF score (3.24% and 2.71%/year). IIF-AMA and ɣGT increased in BN/AMA+ (6.59% and 2.36%) and decreased in PBC (- 4.89%/year and - 3.88%/year). In BN/AMA+ individuals there was positive correlation of ELF with IIF-AMA titer (r = 0.465; p < 0.001) and with anti-PDC-E2 levels (r = 0.239; p < 0.001). Expansion of autoantibody targets along time occurred in 39% BN/AMA+ and 49% PBC patients. The frequency of BN/AMA+ with high probability of having established PBC increased from 7 to 14%. BN/AMA+ individuals present an orchestrated increase in ELF score and humoral autoimmune response over time, indicating an opportunity for early therapeutic intervention and prevention in autoimmunity.
Sections du résumé
BACKGROUND
BACKGROUND
Anti-mitochondria autoantibodies (AMA) occur in > 95% primary biliary cholangitis (PBC) patients. Biochemically normal AMA-positive (BN/AMA+) individuals, occasionally noticed by indirect immunofluorescence (IIF) on HEp-2 cells and confirmed in AMA-specific assays, may represent early stages of PBC. The Enhanced Liver Fibrosis (ELF) score is a surrogate marker for liver fibrosis. This prospective study investigated the ELF score in BN/AMA+ individuals and PBC patients, considering autoantibody avidity and serum levels along the years.
METHODS
METHODS
327 samples from 35 PBC and 59 BN/AMA+ were prospectively obtained in average 3.83 (range 0.50-7.40) years apart. Samples were tested by IIF on rat-kidney (IIF-AMA), western-blot for AMA (WB-AMA), and ELISA for antibodies against pyruvate-dehydrogenase (PDC-E2), gp210, sp100 and CENP-A/B. Anti-PDC-E2 avidity was determined by 6 M urea-elution ELISA. Alkaline phosphatase (ALP), gamma glutamyl transferase (ɣGT) and ELF score were measured by automated methods.
RESULTS
RESULTS
Along the follow-up period BN/AMA+ subjects and PBC patients presented significant increase in serum anti-PDC-E2 (mean 10.45% and 8.86% per year; respectively), anti-PDC-E2 avidity (3.02% and 4.94%/year) and ELF score (3.24% and 2.71%/year). IIF-AMA and ɣGT increased in BN/AMA+ (6.59% and 2.36%) and decreased in PBC (- 4.89%/year and - 3.88%/year). In BN/AMA+ individuals there was positive correlation of ELF with IIF-AMA titer (r = 0.465; p < 0.001) and with anti-PDC-E2 levels (r = 0.239; p < 0.001). Expansion of autoantibody targets along time occurred in 39% BN/AMA+ and 49% PBC patients. The frequency of BN/AMA+ with high probability of having established PBC increased from 7 to 14%.
CONCLUSIONS
CONCLUSIONS
BN/AMA+ individuals present an orchestrated increase in ELF score and humoral autoimmune response over time, indicating an opportunity for early therapeutic intervention and prevention in autoimmunity.
Identifiants
pubmed: 32257066
doi: 10.1186/s13317-019-0120-x
pii: 120
pmc: PMC7065335
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Arthritis Res Ther. 2011 Feb 22;13(1):R30
pubmed: 21342502
Arthritis Rheum. 2003 Oct;48(10):2741-9
pubmed: 14558078
Gastroenterology. 2009 Apr;136(4):1281-7
pubmed: 19208346
Hepatology. 2017 Jan;65(1):152-163
pubmed: 27688145
Eur J Intern Med. 2011 Feb;22(1):77-83
pubmed: 21238899
Clin Exp Immunol. 2004 Jan;135(1):154-8
pubmed: 14678277
J Gastroenterol. 2001 Apr;36(4):248-54
pubmed: 11324728
J Hepatol. 2000 Apr;32(4):561-6
pubmed: 10782903
Lancet. 1996 Nov 23;348(9039):1399-402
pubmed: 8937278
Isr Med Assoc J. 2011 Jan;13(1):55-9
pubmed: 21446239
Clin Liver Dis. 2008 May;12(2):277-88; viii
pubmed: 18456180
Semin Liver Dis. 2005 Aug;25(3):321-6
pubmed: 16143947
Diabetes. 2005 Dec;54 Suppl 2:S25-31
pubmed: 16306336
Hepatology. 2009 Jul;50(1):291-308
pubmed: 19554543
N Engl J Med. 1989 May 25;320(21):1377-80
pubmed: 2716784
Hepatology. 1998 Mar;27(3):656-61
pubmed: 9500690
World J Gastroenterol. 2008 Jun 7;14(21):3313-27
pubmed: 18528929
Liver Int. 2008 Jul;28(6):787-97
pubmed: 18397236
Gastroenterology. 2005 Feb;128(2):297-303
pubmed: 15685541
Hepatology. 2008 Nov;48(5):1549-57
pubmed: 18846542
Hepatol Int. 2012 Dec 05;7(2):775-84
pubmed: 23853697
World J Surg. 2008 May;32(5):688-92
pubmed: 18305995
J Hepatol. 2004 Oct;41(4):677-83
pubmed: 15464251
J Hepatol. 2009 Aug;51(2):237-67
pubmed: 19501929
J Hepatol. 2011 Dec;55(6):1361-7
pubmed: 21703194
Hepatology. 2008 Sep;48(3):871-7
pubmed: 18752324
Gastroenterology. 2004 Dec;127(6):1704-13
pubmed: 15578508
Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):318-28
pubmed: 16741551
N Engl J Med. 2005 Sep 22;353(12):1261-73
pubmed: 16177252
J Hepatol. 2012 Jul;57(1):133-40
pubmed: 22414767
Gut. 2004 Jun;53(6):865-70
pubmed: 15138215
Gastroenterology. 2006 Mar;130(3):715-20
pubmed: 16530513
Hepatology. 2017 Sep;66(3):997
pubmed: 28510307
Expert Opin Pharmacother. 2015 Apr;16(5):633-43
pubmed: 25543678
Clin Dev Immunol. 2004 Jun;11(2):129-33
pubmed: 15330448
Hepatology. 1986 Nov-Dec;6(6):1279-84
pubmed: 3793004
J Hepatol. 2002 Jan;36(1):126-9
pubmed: 11804675
Clin Chim Acta. 2007 May 1;380(1-2):118-21
pubmed: 17321509
Hepatology. 2006 May;43(5):1135-44
pubmed: 16628641